Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Asset Writedowns and Impairment (2018 - 2024)

Organogenesis Holdings (ORGO) has 6 years of Asset Writedowns and Impairment data on record, last reported at $18.8 million in Q2 2024.

  • For Q2 2024, Asset Writedowns and Impairment changed N/A year-over-year to $18.8 million; the TTM value through Dec 2024 reached $18.8 million, up 15544.26%, while the annual FY2024 figure was $18.8 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $18.8 million in Q2 2024 per ORGO's latest filing, up from -$855000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $18.8 million in Q2 2024 and bottomed at -$1.4 million in Q4 2020.
  • Average Asset Writedowns and Impairment over 4 years is $1.8 million, with a median of $733000.0 recorded in 2022.
  • Peak YoY movement for Asset Writedowns and Impairment: skyrocketed 2937.5% in 2020, then plummeted 724.09% in 2022.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at -$1.4 million in 2020, then surged by 109.96% to $137000.0 in 2021, then tumbled by 724.09% to -$855000.0 in 2022, then surged by 2303.74% to $18.8 million in 2024.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $18.8 million in Q2 2024, -$855000.0 in Q4 2022, and $733000.0 in Q3 2022.